James Abely - Psychemedics Vice President General Counsel
| PMD Stock | USD 2.55 0.09 3.41% |
President
Mr. James Abely is Vice President, General Counsel of the Company. In this important role, Jim is responsible for directing and managing all of the company legal activities, including working closely with the company clients, and reports directly to the company CEO. Jim joined Psychemedics in June 2016 as Associate General Counsel, after practicing law for 6 years with the Boston firm of Goodwin Procter LLP, following his graduation from the University of Virginia School of Law. Jim was later promoted to General Counsel. since 2018.
| Tenure | 6 years |
| Address | 5220 Spring Valley Road, Dallas, TX, United States, 75254 |
| Phone | 978 206 8220 |
| Web | https://www.psychemedics.com |
Psychemedics Management Efficiency
The company has Return on Asset of (0.1176) % which means that on every $100 spent on assets, it lost $0.1176. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4763) %, meaning that it generated no profit with money invested by stockholders. Psychemedics' management efficiency ratios could be used to measure how well Psychemedics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.3. The current year's Return On Capital Employed is expected to grow to -0.32. At present, Psychemedics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 663.6 K, whereas Other Assets are forecasted to decline to about 1.2 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Daniel Shine | Thermo Fisher Scientific | 47 | |
| Patrick Weiss | Twist Bioscience Corp | 48 | |
| William King | Danaher | 53 | |
| Lloyd Sanders | Myriad Genetics | 57 | |
| Sam Samad | Illumina | 48 | |
| Patrick Durbin | Thermo Fisher Scientific | 51 | |
| Thomas Loewald | Thermo Fisher Scientific | 52 | |
| Patrick Kaltenbach | Agilent Technologies | 53 | |
| Robert Lutz | Danaher | 62 | |
| Samraat Raha | Agilent Technologies | 51 | |
| Alicia Rodriguez | Agilent Technologies | N/A | |
| Daniel Comas | Danaher | 55 | |
| William Daniel | Danaher | 53 | |
| Jacob Thaysen | Agilent Technologies | 49 | |
| Andrew Thomson | Thermo Fisher Scientific | 49 | |
| Omead Ostadan | Illumina | 46 | |
| Mark Oene | Illumina | 45 | |
| Paula Green | Twist Bioscience Corp | 56 | |
| Virginia Drosos | Myriad Genetics | 53 | |
| Karen McGinnis | Illumina | 50 | |
| Mark Stevenson | Thermo Fisher Scientific | 57 | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.12 |
Psychemedics Leadership Team
Elected by the shareholders, the Psychemedics' board of directors comprises two types of representatives: Psychemedics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Psychemedics. The board's role is to monitor Psychemedics' management team and ensure that shareholders' interests are well served. Psychemedics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Psychemedics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Clinton Allen, Independent Director | ||
| Charles IV, Ex VP | ||
| Harry Connick, Independent Director | ||
| James Abely, Vice President General Counsel | ||
| Fred Weinert, Independent Director | ||
| Werner Baumgartner, Founder | ||
| Annette Baumgartner, Founder | ||
| Sarah Ashby, VP Counsel | ||
| Patrick Kinney, Secretary | ||
| Brian Hullinger, CEO President | ||
| Walter Tomenson, Independent Director | ||
| Charles Doucot, Executive Vice President | ||
| Michael Weisenhoff, Principal Manager | ||
| Raymond Kubacki, Chairman, CEO and Pres | ||
| James Dyke, Corporate VP of Sales and Marketing | ||
| Shannon Shoemaker, Chief Officer | ||
| Michael Schaffer, VP of Laboratory Operations | ||
| Neil Lerner, Vice President - Finance, Treasurer | ||
| Daniella Mehalik, Vice Finance |
Psychemedics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Psychemedics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | (0.17) % | ||||
| Current Valuation | 15.64 M | ||||
| Shares Outstanding | 5.81 M | ||||
| Shares Owned By Insiders | 22.70 % | ||||
| Shares Owned By Institutions | 22.30 % | ||||
| Number Of Shares Shorted | 16.88 K | ||||
| Price To Earning | 92.08 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Psychemedics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Psychemedics Stock analysis
When running Psychemedics' price analysis, check to measure Psychemedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Psychemedics is operating at the current time. Most of Psychemedics' value examination focuses on studying past and present price action to predict the probability of Psychemedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Psychemedics' price. Additionally, you may evaluate how the addition of Psychemedics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Psychemedics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psychemedics. If investors know Psychemedics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psychemedics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Dividend Share 0.07 | Earnings Share (0.72) | Revenue Per Share 3.85 | Quarterly Revenue Growth (0.12) |
The market value of Psychemedics is measured differently than its book value, which is the value of Psychemedics that is recorded on the company's balance sheet. Investors also form their own opinion of Psychemedics' value that differs from its market value or its book value, called intrinsic value, which is Psychemedics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psychemedics' market value can be influenced by many factors that don't directly affect Psychemedics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psychemedics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Psychemedics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psychemedics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.